查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714643

按藥物類型、技術、治療領域和最終用戶分類的藥物研發市場—2025-2030 年全球預測

Drug Discovery Market by Drug Type, Technology, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年藥物研發市場規模將達623.8億美元，2024年將達711.2億美元，年複合成長率為14.10%，到2030年將達到1571.3億美元。

全面介紹藥物發現的演變

主要市場統計數據
基準年2023年 623.8億美元
預計2024年 711.2億美元
預測年份 2030 1571.3億美元
複合年成長率（%） 14.10%

近年來，藥物研發領域已經超越了傳統的研究典範。這一轉變是由科學創新、先進技術以及不斷變化的監管和市場環境共同推動的。相關人員努力加速從實驗室突破到可行治療解決方案的進程，業界利用多方面見解和尖端方法的努力比以往任何時候都更加重要。

計算生物學、實驗通訊協定自動化和資料科學的整合的最新趨勢正在重新定義早期藥物開發的進行方式。各組織擴大投資於敏捷技術，這些技術不僅可以簡化高通量篩檢流程，還可以提高生物分析的準確性。這些努力使得藥物發現生命週期更加互聯、反應更快，其中迭代學習和快速原型製作正在成為常態。這樣，該行業就可以滿足日益成長的有效治療方法需求，同時克服臨床挑戰。

此外，學術界、委外研發機構和大型製藥企業之間的合作為該行業創造了合作基調。這種對多學科夥伴關係和跨職能研究的日益重視凸顯了當今藥物發現領域的變革議程，並為針對複雜疾病特徵的創新治療性介入奠定了基礎。

重新定義藥物研發格局的轉捩點

藥物研發領域正在經歷變革，重新定義其基本運作架構。這種變化的主要驅動力是技術的快速進步，它將曾經繁瑣的研究和開發週期轉變為精簡的、資料主導的流程。隨著新技術不斷融入傳統研究工作流程，業界正見證科學嚴謹性與自動化和計算建模的無縫整合。

人工智慧、增強成像技術和強大的資料分析的進步不僅加速了先導化合物，而且提高了臨床檢驗的準確性。這種轉變與全球對個人化醫療的重視相輔相成，預計個人化醫療將帶來更有效的治療方法，解決患者群體的異質性。此外，不斷發展的法律規範支援更快的核准流程，同時不影響安全性，從而培育出重視創新和敏捷性的生態系統。

這種動態培育了一種以合作為重的文化。研究機構、生物技術新興企業和成熟製藥公司正在匯集資源和專業知識來應對複雜的治療挑戰。技術和科學的廣泛融合為藥物發現的新時代奠定了基礎，其中管理風險和投資尖端工具對於保持長期競爭優勢至關重要。

關鍵的細分洞見將塑造未來的研究領域

仔細觀察市場區隔就會發現，藥物研發產業內存在許多層次的專業化。該行業根據藥物類型進行細分，詳細研究區分生物製藥和小分子藥物。這種區別對於開發平臺、監管途徑和市場引入策略具有重要意義。

在技​​術方面，生物分析儀器、生物晶片、生物資訊等各種尖端工具已被引入並成為現代研究的支柱。組合化學、高通量篩檢和奈米技術等先進技術也處於前沿，藥物基因組學正在為個人化醫療和標靶治療鋪平道路。這些技術領域透過加速藥物開發和確保治療標靶的精準性而增加了巨大的價值。

根據治療領域進一步細分，突顯了藥物發現工作的針對性應用。心血管疾病、消化器官系統、感染疾病和免疫疾病、神經病學和腫瘤學等重點關注領域代表了需要獨特研究方法的多樣化臨床環境。最後，根據學術界、研究機構、委外研發機構和大型製藥公司等最終用戶進行細分，可以提供多層次的市場動態圖景。以這種方式整合細分洞察，可使相關人員根據特定的市場需求和臨床挑戰調整策略，從而最大限度地提高研究收益和臨床成功率。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 製藥和生物製藥產業研發成本不斷增加
      • 管理臨床前研究期間產生的大量資料的需求日益成長
      • 政府對藥物研發平台發展的積極支持
    • 限制因素
      • 藥物研發需要大量資金
    • 機會
      • 新的企業合作拓展了藥物研發能力
      • 藥物研發的技術進步與創新
      • 利用人工智慧雲創建簡化、自動化的藥物研發方法
    • 任務
      • 藥物研發中使用動物的嚴格標準
  • 市場區隔分析
    • 藥物類型：品牌學名藥推動小分子藥物的需求
    • 技術：擴大早期生物分析儀器和高通量篩檢的使用
    • 治療領域：腫瘤藥物研發中對藥物發現的需求日益增加
    • 最終用戶：製藥和生物技術公司擴大利用藥物發現來開發新的和改良的藥物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 藥物研發市場（依藥物類型）

  • 生物製藥
  • 小分子藥物

第7章 藥物研發市場（依技術）

  • 生物分析儀器
  • 生物晶片
  • 生物資訊學
  • 組合化學
  • 高通量篩檢
  • 奈米科技
  • 藥物基因組學

第8章 藥物研發市場（依治療領域）

  • 心血管疾病
  • 消化器官系統疾病
  • 感染疾病及免疫系統疾病
  • 神經病學
  • 腫瘤學

第9章 藥物研發市場（依最終用戶分類）

  • 學術和研究機構
  • 合約研究組織
  • 製藥公司

第 10 章：美洲藥物研發市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第 11 章：亞太藥物研發市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 12 章歐洲、中東和非洲的藥物研發市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Alkem Laboratories Ltd
  • Amgen Inc.
  • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • Astrazeneca PLC
  • Atomwise, Inc.
  • BenevolentAI
  • Bio-Rad Laboratories, Inc.
  • BioSymetrics Inc.
  • Charles River Laboratories International, Inc.
  • Chembridge Corporation
  • Cloud Pharmaceuticals, Inc.
  • Dalriada Drug Discovery
  • Deciphera Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • Exscientia PLC
  • F. Hoffmann-La Roche Ltd.
  • GENFIT SA
  • Incyte Corporation
  • International Business Machines Corporation
  • Intra-Cellular Therapies Inc.
  • Kvantify
  • Lantern Pharma Inc.
  • Merck KGaA
  • Microsoft Corporation
  • NVIDIA Corporation
  • PerkinElmer, Inc.
  • Pharmacelera SL
  • Piramal Group
  • Recursion Pharmaceuticals, Inc.
  • Sanofi SA
  • Schrodinger, Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA0516F

The Drug Discovery Market was valued at USD 62.38 billion in 2023 and is projected to grow to USD 71.12 billion in 2024, with a CAGR of 14.10%, reaching USD 157.13 billion by 2030.

A Comprehensive Introduction to the Evolution of Drug Discovery

KEY MARKET STATISTICS
Base Year [2023] USD 62.38 billion
Estimated Year [2024] USD 71.12 billion
Forecast Year [2030] USD 157.13 billion
CAGR (%) 14.10%

In recent years, the field of drug discovery has experienced an evolution that transcends traditional research paradigms. This transformation is driven by the convergence of scientific innovation, advanced technology, and an ever-changing regulatory and market environment. The industry's commitment to leveraging multidimensional insights and cutting-edge methodologies is now more critical than ever, as stakeholders strive to accelerate the journey from laboratory breakthroughs to viable therapeutic solutions.

Recent advancements in computational biology, automation of experimental protocols, and integration of data science have redefined how early-stage drug development is conducted. Organizations are increasingly investing in agile technologies that not only streamline high throughput screening processes but also enhance bioanalytical accuracy. These efforts have led to a more interconnected and responsive drug discovery lifecycle, where iterative learning and rapid prototyping are becoming the norm. In doing so, the sector positions itself to meet the growing demand for effective therapies while overcoming clinical challenges.

Furthermore, collaboration across academia, contract research organizations, and large pharmaceutical companies has set a collaborative tone for the industry. This heightened focus on interdisciplinary partnerships and cross-functional research underscores the transformative agenda of today's drug discovery landscape, laying the foundation for innovative therapeutic interventions that address complex disease profiles.

Transformative Shifts Redefining the Drug Discovery Landscape

The drug discovery arena is undergoing transformative shifts that have redefined its fundamental operational framework. A significant driver of this change is the rapid pace of technological advancement, which is turning once cumbersome cycles of research and development into streamlined, data-driven processes. As emerging technologies continue to integrate into traditional research workflows, the industry witnesses a seamless blend of scientific rigor with automation and computational modeling.

Advancements in artificial intelligence, enhanced imaging techniques, and robust data analytics are not only accelerating the identification of lead compounds but also enhancing the precision of clinical validation. This shift is further complemented by a global emphasis on personalized medicine, where tailored therapeutic approaches promise to address the heterogeneity of patient populations more effectively. Moreover, evolving regulatory frameworks are supporting faster approval processes without compromising safety, thereby cultivating an ecosystem that prizes innovation and agility.

These dynamic changes have fostered a climate where collaboration is paramount. Research institutions, biotech startups, and established pharmaceutical companies are pooling resources and expertise to tackle complex therapeutic challenges. Such broad-based integration of technology and science is setting the stage for a new era in drug discovery, where risk management and investment in state-of-the-art tools are pivotal to sustaining long-term competitive advantage.

Key Segmentation Insights Shaping the Future Research Arena

A meticulous examination of market segmentation reveals multiple layers of specialization within drug discovery. The industry is segmented based on drug type, where an in-depth study distinguishes between biologic drugs and small molecule drugs. This differentiation has profound implications on developmental pipelines, regulatory pathways, and market adoption strategies.

From a technology perspective, the landscape has embraced a range of sophisticated tools, including bioanalytical instruments, biochips, and bioinformatics, which form the backbone of modern research. Advanced techniques such as combinatorial chemistry, high throughput screening, and nanotechnology are also at the forefront, while pharmacogenomics is paving the way towards personalized care and targeted therapies. These technological segments contribute significant value by expediting drug development and ensuring precision in therapeutic targeting.

Further segmentation based on therapeutic areas underscores the targeted application of drug discovery efforts. Critical focus areas such as cardiovascular disease, digestive system diseases, infectious and immune system diseases, neurology, and oncology illustrate the diverse clinical settings that demand distinct research approaches. Finally, segmentation based on end users, which spans the academic community, research institutions, and contract research organizations, as well as large pharmaceutical companies, presents a layered view of market dynamics. This integration of segmentation insights empowers stakeholders to align strategies with specific market needs and clinical challenges, thereby maximizing research returns and clinical success.

Based on Drug Type, market is studied across Biologic Drugs and Small Molecule Drugs.

Based on Technology, market is studied across Bioanalytical Instruments, Biochips, Bioinformatics, Combinatorial Chemistry, High Throughput Screening, Nanotechnology, and Pharmacogenomics.

Based on Therapeutic Area, market is studied across Cardiovascular Disease, Digestive System Diseases, Infectious & Immune system Diseases, Neurology, and Oncology.

Based on End User, market is studied across Academics & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.

Regional Insights: A Global Perspective on Drug Discovery Innovation

The regional dynamics of drug discovery further enrich the analysis of this rapidly transforming industry. The Americas, with its robust infrastructural support for research and development, continues to lead in innovation. Intricate networks of academic institutions, biotech startups, and major pharmaceutical hubs create an environment ripe for transformative research and seamless commercialization of new therapies.

In Europe, Middle East, and Africa, a unique blend of regulatory precision and market demand fosters an ecosystem where breakthrough innovations reliably move from bench to bedside. This region's commitment to integrating advanced technological infrastructures with conventional research methodologies is notable, as it attracts significant global investment and collaborative efforts.

Across the Asia-Pacific region, rapid economic growth coupled with a surge in population-based studies and government-supported healthcare initiatives has accelerated advancements in drug discovery. In this diverse market, strategic partnerships and localized research initiatives play pivotal roles, driving faster adoption of cutting-edge technologies and broadening the scope of therapeutic research. These regional insights highlight a global breadth of innovation that reinforces the necessity for decentralized yet coordinated approaches to drug discovery.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Georgia, Illinois, Indiana, Michigan, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Insights in the Evolving Drug Discovery Fabric

Analyzing the contributions of key players in the market reveals the competitive intensity within the drug discovery space. Prominent companies such as Abbott Laboratories, Agilent Technologies, Inc., and Alacrita Holdings Limited are continually pushing the envelope by developing and integrating groundbreaking technologies. These organizations, alongside leaders like Alkem Laboratories Ltd and Amgen Inc., are setting benchmarks in drug development practices.

The influence of firms such as Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, and Atomwise, Inc. is evident in their relentless pursuit of innovative therapy development. Investments by BenevolentAI and Bio-Rad Laboratories, Inc. further highlight the drive towards harnessing artificial intelligence and data analytics to streamline discovery processes. Moreover, contributions from organizations like BioSymetrics Inc. and Charles River Laboratories International, Inc. have played a crucial role in refining experimental protocols and enhancing regulatory compliance.

Other notable companies such as Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, and Deciphera Pharmaceuticals, Inc. are strategically positioned to leverage emerging computational tools and novel research methodologies. The strategic alliances and technology integrations championed by Eli Lilly and Company, Evotec SE, Exscientia PLC, and F. Hoffmann-La Roche Ltd. underscore the importance of collaborative innovation. With further contributions from GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, and Piramal Group, the market is characterized by a rich interplay of scientific expertise and commercial acumen. Continuing this momentum, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc. exemplify the dynamic and integrated nature of modern drug discovery endeavors.

The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Alkem Laboratories Ltd, Amgen Inc., Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Evotec SE, Exscientia PLC, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders Navigating Change

Industry leaders should adopt a dynamic approach to address current challenges and sustain future growth. Embracing cross-disciplinary research efforts and investing in next-generation technologies is imperative for maintaining competitive advantage. Decision-makers are encouraged to prioritize initiatives that facilitate collaboration between academic research teams, contract research organizations, and established pharmaceutical companies, thereby creating a unified framework for agile innovation.

For organizations aiming to reduce time-to-market, integrating high throughput screening, advanced bioinformatics, and nanotechnology can result in more efficient identification of lead compounds. Investing in sophisticated bioanalytical instruments and leveraging combinatorial chemistry will further enhance the fidelity and speed of discovery processes. Such strategic investments not only optimize operational workflows but also foster a culture of innovation and continuous improvement.

It is advisable for stakeholders to closely monitor emerging regulatory trends and seek strategic partnerships that align with evolving market demands. Building robust digital infrastructures capable of managing large datasets and predictive analytics is a crucial step in driving success. Furthermore, tailoring therapeutic strategies to target specific clinical areas, such as oncology and neurology, will likely yield higher returns on investment. Ultimately, a cohesive strategy that blends technological adoption with market-specific insights will empower industry leaders to effectively navigate the rapidly evolving landscape.

Conclusion: Embracing Change for a Future-Ready Drug Discovery Ecosystem

The shifting paradigms within drug discovery underscore a transformative era marked by technological sophistication, strategic segmentation, and expansive global collaborations. In summary, the industry is reaping the benefits of advanced computational methods, dynamic regional investments, and the collective expertise of pioneering companies. These factors converge to create a fertile ground for innovation that is both economically and scientifically sustainable.

A robust drug discovery framework today is defined by its openness to disruptive technologies and cross-sectoral partnerships. As the market continues to evolve, stakeholders across the spectrum must continually reassess investment strategies while embracing integrated workflows that streamline the research and development process. The synthesis of advanced technological integrations with strategic market insights ensures that the drug discovery ecosystem is poised to deliver novel therapeutic solutions that address unmet clinical needs.

In essence, the future of drug discovery hinges on our ability to harness innovation, collaborate across traditional silos, and implement forward-thinking solutions that respond to the challenges of an increasingly complex global landscape. The journey ahead is one of both opportunity and responsibility, requiring all players to be agile, innovative, and collaborative in their pursuit of scientific excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
      • 5.1.1.2. Increasing need to manage large data generated during preclinical studies
      • 5.1.1.3. Favorable government support for the development of drug discovery platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of extensive capital for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging collaborations among companies to expand their drug discovery capabilities
      • 5.1.3.2. Technological advancements and innovations in drug discovery
      • 5.1.3.3. Use of AI cloud to create a streamlined and automated approach in drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent norms for animal usage in drug discovery
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
    • 5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
    • 5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
    • 5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Biologic Drugs
  • 6.3. Small Molecule Drugs

7. Drug Discovery Market, by Technology

  • 7.1. Introduction
  • 7.2. Bioanalytical Instruments
  • 7.3. Biochips
  • 7.4. Bioinformatics
  • 7.5. Combinatorial Chemistry
  • 7.6. High Throughput Screening
  • 7.7. Nanotechnology
  • 7.8. Pharmacogenomics

8. Drug Discovery Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Disease
  • 8.3. Digestive System Diseases
  • 8.4. Infectious & Immune system Diseases
  • 8.5. Neurology
  • 8.6. Oncology

9. Drug Discovery Market, by End User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies

10. Americas Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Exscientia PLC partners with AWS to harness AI and cloud technology for accelerating drug discovery and reducing costs
    • 13.3.2. Enzene Biosciences launches new drug discovery division offering integrated services
    • 13.3.3. Emory University's Center for New Medicines accelerates drug discovery with advanced technology for improved patient outcomes and collaborative research.
    • 13.3.4. Oregon Therapeutics partners with Lantern Pharma to advance XCE853 development using RADR AI platform, targeting drug-resistant cancers
    • 13.3.5. Xaira Therapeutics launches with over USD 1 billion funding to revolutionize AI-driven drug discovery with innovative machine learning models
    • 13.3.6. bioXcelerate launches PleioGraph AI tool to revolutionize drug discovery, cutting costs and accelerating treatments by 100x
    • 13.3.7. UC Berkeley's Molecular Therapeutics Initiative (MTI) aims to accelerate breakthrough treatments for neurological, metabolic diseases, and cancer through interdisciplinary collaboration
    • 13.3.8. Danish quantum computing firm Kvantify unveils Kvantify Koffee to revolutionize drug discovery with expedited screening, cost reduction, and future-proof technology integration
    • 13.3.9. Washington University and Deerfield Management partner to launch VeritaScience, committing USD 130 million to advance drug discovery and development
    • 13.3.10. Arena BioWorks opens in Kendall Square with USD 500 million to accelerate drug discovery and market innovative medicines.
    • 13.3.11. Evommune and Accutar Biotechnology announce AI drug discovery collaboration
    • 13.3.12. IGC Pharma signs agreement to adopt AI solutions into drug discovery
    • 13.3.13. University of Tsukuba and Astellas Pharma Inc. confirm a strategic partnership
    • 13.3.14. Sosei and PharmEnable collaborate on another neurological drug
    • 13.3.15. Novo Nordisk and Evotec launch translational drug discovery accelerator
    • 13.3.16. Genesis raises USD 200 million for AI drug discovery research
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. NVIDIA Corporation
    • 13.4.2. F. Hoffmann-La Roche Ltd.
    • 13.4.3. Exscientia PLC
    • 13.4.4. Alkem Laboratories Ltd

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Alacrita Holdings Limited
  • 4. Alkem Laboratories Ltd
  • 5. Amgen Inc.
  • 6. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • 7. Astrazeneca PLC
  • 8. Atomwise, Inc.
  • 9. BenevolentAI
  • 10. Bio-Rad Laboratories, Inc.
  • 11. BioSymetrics Inc.
  • 12. Charles River Laboratories International, Inc.
  • 13. Chembridge Corporation
  • 14. Cloud Pharmaceuticals, Inc.
  • 15. Dalriada Drug Discovery
  • 16. Deciphera Pharmaceuticals, Inc.
  • 17. Eli Lilly and Company
  • 18. Evotec SE
  • 19. Exscientia PLC
  • 20. F. Hoffmann-La Roche Ltd.
  • 21. GENFIT SA
  • 22. Incyte Corporation
  • 23. International Business Machines Corporation
  • 24. Intra-Cellular Therapies Inc.
  • 25. Kvantify
  • 26. Lantern Pharma Inc.
  • 27. Merck KGaA
  • 28. Microsoft Corporation
  • 29. NVIDIA Corporation
  • 30. PerkinElmer, Inc.
  • 31. Pharmacelera SL
  • 32. Piramal Group
  • 33. Recursion Pharmaceuticals, Inc.
  • 34. Sanofi S.A
  • 35. Schrodinger, Inc.
  • 36. Shimadzu Corporation
  • 37. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DRUG DISCOVERY MARKET MULTI-CURRENCY
  • FIGURE 2. DRUG DISCOVERY MARKET MULTI-LANGUAGE
  • FIGURE 3. DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 4. DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023